Prof. Wolfram C. M. Dempke
University of Munich, Germany

Email: [email protected]

Qualifications
2019 DBA., University of Middlesex, UK
2015 Ph.D., Open University of Hamburg, Germany
2008 MD., University of Munich, Germany
2000 MD., University of Halle, Germany

Publications (Selected)

1. Fenchel, K., Geuther, G., Wang, S. Y., et al. (2026). Use of melphalan flufenamide (melflufen) in difficult-to-treat patients with multiple myeloma and renal insufficiency or EMD. Oncology Research and Treatment, 49(Suppl. 1), 118.
2. Dempke, W. C. M., Fenchel, K., & Reinmuth, N. (2026). Zipalertinib-A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR Mutations. Cancers, 18(2), Article 323.
3. Fenchel, K., Geuther, G., & Dempke, W. (2025). Successful melphalan flufenamide (melflufen) therapy in patients with severe renal insufficiency. Blood, 146(Suppl. 1), 7521–7522.
4. Jing, Y., Zhao, Y., Zhou, Z., et al. (2025). Real-world efficacy of atezolizumab combined with etoposide and platinum chemotherapy in extensive-stage small cell lung cancer: a retrospective cohort study. Journal of Thoracic Disease, 17(7), 5210–5222.
5. Papayannidis, C., Martinelli, G., Wadolowska, A., et al. (2025). Liposomal annamycin in combination with cytarabine for treatment of acute myeloid leukemia (AML). Annals of Hematology, 104(Suppl. S), S2.
6. Dempke, W. C. M., & Fenchel, K. (2025). TET2 cascade: a novel regulator of chromatin structure and leukaemogenesis. Signal Transduction and Targeted Therapy, 10(1), Article 6.
7. Du, J., Zhang, Q., Tian, L., et al. (2024). Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study. Journal of Thoracic Disease, 16(12), 8669–8683.
8. Dempke, W. C. M., & Fenchel, K. (2024). Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review. Translational Cancer Research, 13(11), 6540–6549.
9. Zielinski, R., Grela, K., Peng, S., et al. (2024). Annamycin: Opening New Doors for Organotropic Targeting of Primary and Metastatic Lung Cancer. Journal of Thoracic Oncology, 19(10, Suppl. S), S310–S311.
10. Fang, Z., Wu, X., Xiao, L., et al. (2024). Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study. Journal of Thoracic Disease, 16(5), 3338–3349.
11. Zielinski, R. J., Grela, K., Cardenas-Zuniga, R., et al. (2024). Non-cardiotoxic properties of annamycin, a clinically evaluated anthracycline and potent topoisomerase 2 β poison. Cancer Research, 84(7, Suppl. S), LB180.
12. Papayannidis, C., Wadolowska, C., Sica, S., et al. (2023). Preliminary Results from a Phase 1/2 Study of Liposomal Annamycin (L-ANN) in Combination with Cytarabin for the Treatment of Patients with Acute Myeloid Leukemia (AML) That Is Refractory to or Relapsed (r/r) after Induction Therapy. Blood, 142(Suppl. 1), 616.
13. Dempke, W. C. M., Desole, M., Chiusolo, P., et al. (2023). Targeting the undruggable: menin inhibitors ante portas. Journal of Cancer Research and Clinical Oncology, 149(11), 9451–9459.
14. Dempke, W. C. M., Zielinski, R., Winkler, C., et al. (2023). Anthracycline-induced cardiotoxicity-are we about to clear this hurdle?. European Journal of Cancer, 185, 94–104.
15. Xu, X., Chen, L., Bian, D., et al. (2022). efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis (vol 11, pg 1631, 2022). Translational Lung Cancer Research, 11(12), 2610–2611.
16. Dempke, W. C. M., Reuther, S., Hamid, Z., & Thoennissen, N. H. (2022). Oncogene alterations in non-small cell lung cancer-have we MET a new target?. Translational Lung Cancer Research, 11(10), 1977–1981.
17. Liang, W., Cai, K., Cao, Q., et al. (2022). International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Translational Lung Cancer Research, 11(9), 1742–1762.
18. Bian, D., Jiang, S., Xiong, Y., et al. (2022). Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis. Translational Lung Cancer Research, 11.
19. Reuther, S., Floegel, K., Ceusters, G., et al. (2022). Contamination Rate of Cryopreserved Umbilical Cord Blood Is Inverse Correlated with Volume of Sample Collected and Is also Dependent on Delivery Mode. Stem Cells Translational Medicine, 11(6), 604–612.
20. Dempke, W. C. M., Fenchel, K., Reuther, S., & Murphy, M. F. (2022). Durvalumab plus novel agents in non-small cell lung cancer-a new COAST on the horizon? Comment. Translational Lung Cancer Research, 11(4), 697–701.